Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +70.95%
#3 Pons Pons +31.22%
#4 MetaDAO MetaDAO +28.82%
#5 Rain Rain +22.55%
#6 Bedrock Bedrock +21.25%
#7 Ontology Gas Ontology Gas +17.40%
#8 Prom Prom +14.68%
#9 Humanity Humanity +14.44%
#10 Stacks Stacks +13.98%
Coin of the day
QuantixAI QuantixAI
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
Rang in Aktien #20199
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Aktienkurs
$10.25
Zuletzt synchronisiert: 2024-02-22
Marktkapitalisierung
$137.83M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
CN
Handel Gracell Biotechnologies Inc. (GRCL)

Kategorie

Healthcare
Kursverlauf für Gracell Biotechnologies Inc. (GRCL)
Höchster Schlusskurs: $10.24 am 2024-02-01

Niedrigster Schlusskurs: $22.88 am 2021-01-01
Kursverlauf der Aktie von Gracell Biotechnologies Inc. von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 60.59%
2023 155.25%
2022 -61.61%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 50.56%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 525.80%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.47 -12.71%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 8.67%
CH